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Summary
With the outcome to demonstrate the efficacy of calcium to pre-
vent the incidence of fractures many randomized controlled trials
have been performed in the past two decades, with conflicting
results. A RR of 0.86 for non-vertebral fractures and a RR of 0.91
for hip fractures on eight trials were demonstrated. Calcium sup-
plementation is considered particularly important when base-
line calcium intake is low. More recently WHI CaD Study indi-
cated that calcium supplements with or without vitamin D re-
present a factor risk for cardiovascular events. On the other hand
the beneficial effect of a correct calcium intake in attaining and
maintaining bone mass across the life is largely demonstrated.
There is an urgent need for more research to gain insight into
the mechanisms of the adverse vascular effect of calcium. Mo-
reover, more extensive data about the incidence of cardiova-
scular adverse events coming from randomized controlled in-
tervention trials in osteoporosis, in which calcium plus Vitamin
D were utilized, might be achieved.
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Introduction
Calcium plays a fundamental role in promoting bone health, as well
as in blood coagulation, muscle contraction and regulation of ner-
ve excitability. 1200 mg/day of calcium for men and women aged
over 50 years has been proposed by the US National Academy of
Sciences as an adequate intake, whereas 1000 mg/day is considered
sufficient for younger adults (1). European guideline recommend lower
dosages, 800 mg/day for women aged 50-65 years. In the elderly,
both those living in the community as well as institutions, the dietary
calcium intake is commonly low. In a cohort of elderly community-
dwelling French women calcium intake was calculated to be 569
mg/day (2). Our experience confirms these data, underlining that mean
calcium intake in elderly people may be sometime less than 600
mg/day (3). New estimates from NHANES shows that American adults
are characterized by an age-related decline in calcium intake, par-
tly explained by a concurrent decline in energy intake, while sup-
plemental calcium use are highest in older age groups (4). Moreo-
ver patients with documented osteoporosis generally also have an
inadequate dietary calcium intake. A review of baseline data from
six of the major osteoporosis trials revealed that 85% of participants
had calcium intakes <1200 mg at study entry, with a mean of 727
mg/day (5). Nevertheless, definition of the optimal calcium intake is
hampered by several uncertainties. It was suggested that a calcium
intake >800 mg/day is not necessary for preventing an increase of
serum PTH when serum 25(OH)D > 25 nmol/l (6). A meta-analysis
of prospective cohort studies and clinical trials did not show a de-
creased fracture risk with a high vs. low calcium intake (7). In the Wo-
men’s Health Initiative, a trial in 36,282 women with calcium 1000
mg/day and vitamin D 400 IU/day vs. double placebo, the inciden-
ce of kidney stones increased with 17%. Low intakes may cause se-
condary hyperparathyroidism, while high intakes carry a risk of side
effects. A total intake from diet and supplements of about 1000 mg/d
probably is sufficient and safe.
Usually calcium supplementation is associated with vitamin D. Vi-
tamin D is essential for maintaining calcium homeostasis.10, mainly
regulating intestinal calcium absorption.  Circulating 25(OH)D levels
indicative of a deficiency state is typically defined as <25 nmol/l. In
the presence of inadequate vitamin D status, calcium absorption is
reduced  and there is a homeostatic increase in parathyroid hormone
levels with a consequent stimulation of bone resorption and acce-
lerated bone loss (8). In elderly people  vitamin D deficiency in com-
mon because the decreased exposure to sunshine and reduced ca-
pacity of the skin to synthesize vitamin D. Muscular strength is also
regulated by vitamin D 13: lower than 25-30 nmol/l vitamin D sta-
tus  in older subjects is associated with muscular weakness, decreased
physical performance and increased propensity to falls. On the other
hand falls are considered one of the main risk factor for  pathologi-
cal fractures. 
With the outcome to demonstrate the efficacy of calcium plus vita-
min D to prevent the incidence of fractures many randomized con-
trolled trials have been performed in the past two decades, with con-
flicting results. The daily oral dosage of calcium ranged from 500 to
1200 mg, and for Vitamin D from 400 to 800 IU. In general, more
positive results in terms of fracture risk reduction or decrease of fall
incidence  were observed using Vitamin D 800 IU/day. The percentage
of reduction of  PTH levels seems to not correlate with antifracturative
efficacy (9). A recent meta-analysis performed on 12 randomized con-
trolled trials reports, together the correction of secondary hyperpa-
rathyroidism, a RR of 0.86 for non-vertebral fractures and a RR of
0.91 for hip fractures on eight trials, underlining the relationship
between efficacy  and the optimal dose of 800 IU/day of Vitamin D
(10). As regards calcium intake, calcium supplementation is parti-
cularly important when baseline calcium intake is low. Besides Vi-
tamin D, a crucial problem also for calcium supplementation is com-
pliance and persistence: adherence with medication in osteoporo-
sis is frequently less than optimal and this may modify treatment ef-
fect. In our opinion the use of calcium-dense foods could be en-
couraged to maintain adequate calcium intake across the lifespain.
Considering that low calcium intake and poor Vitamin D status play
a significant role to increase osteoporotic fracture risk, we believe
that calcium and Vitamin D must be considered determinant com-
ponents in the prevention of bone loss and falls,  and in the treat-
ment of osteoporosis together with antiresorptive or bone-forming
agents. 
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A study performed in New Zealand in which calcium supplement was
administered at the dosage of 1000 mg/day showed an increase in
combined cardiovascular end-points compared with the placebo group
(11). Particularly, myocardial infarction was more commonly repor-
ted in the calcium group than in the placebo group (45 events in 31wo-
men vs 19 events in 14 women, P=0.01); the composite end point
of myocardial infarction, stroke, or sudden death was also more com-
mon in the calcium group (101 events in 69 women vs. 54 events
in 42 women, P=0.008). A subsequent meta- analysis confirmed that
calcium supplements (without co-administration of vitamin D) are as-
sociated with an increased risk of myocardial infarction (12). The meta-
analysis examined 15 trials: in the five studies contributing patient
level data, 143 people allocated to calcium had a myocardial infarction
compared with 111 allocated to placebo (hazard ratio 1.31, 95% con-
fidence interval 1.02 to 1.67, P=0.035); non-significant increases oc-
curred as regards the incidence of stroke. Moreover, in 11 trial le-
vel data similar results were appreciated: 296 people had a myocardial
infarction (166 allocated to calcium, 130 to placebo), with an increased
incidence of myocardial infarction in those allocated to calcium (rr
1.27, 95% confidence interval 1.01 to 1.59, P=0.038) (12). 
The effects of personal calcium supplement use on cardiovascular
risk were examined also in the Women’s Health Initiative Cal-
cium/Vitamin D Supplementation Study (WHI CaD Study). WHI CaD
Study is a  seven year, randomised, placebo controlled trial that analy-
zed 36 282 community dwelling postmenopausal women in which
calcium and vitamin D were administered at the dosage of 1g and
400 IU per day, respectively (13). In the 16.718 women which re-
presents the 46% of the population study, who were not taking per-
sonal calcium supplements at randomisation the hazard ratios for
cardiovascular events with calcium and vitamin D ranged from 1.13
to 1.22 (P=0.05 for clinical myocardial infarction or stroke, P=0.04
for clinical myocardial infarction or revascularisation), whereas car-
diovascular risk did not increase in the women taking personal cal-
cium supplements at randomisation. The meta-analyses of three pla-
cebo controlled trials showed that calcium and vitamin D increased
the risk of myocardial infarction (relative risk 1.21, P=0.04), stroke
(1.20, P=0.05), and the composite of myocardial infarction or
stroke (1.16, P=0.02). On the other hand, as regards meta-analy-
ses of placebo controlled trials of calcium or calcium and vitamin D,
complete trial-level data were available for 28 072 participants from
eight trials of calcium supplements and the WHI CaD participants
not taking personal calcium supplements: the number of subjects who
experienced incident myocardial infarction or stroke was 1384, with
an increased  risk for myocardial  infarction (relative risk 1.24, P=0.004)
and for composite of myocardial infarction or stroke (1.15, P=0.009)
in calcium or calcium and Vitamin D group. From these data the
Authors conclude that calcium supplements with or without vitamin
D represent a factor risk for cardiovascular events, especially myo-
cardial infarction; at the same time, they underline that previous re-
sults of the Women’s Health Initiative which reported no effect of cal-
cium and vitamin D supplements on cardiovascular events, were ob-
scured by the widespread use of personal calcium supplements  at
study entry. The conclusive remarks of the paper indicate that the
use of calcium supplementation in osteoporosis management
should be reassessed. However many questions remain on the ta-
ble: is it sufficient a correct lifestyle to prevent bone fragility and frac-
tures? May dietary calcium administration induce similar effect in main-
taining bone mass as oral calcium supplementation? The beneficial
effect of a correct calcium intake in attaining and maintaining bone
mass across the life is largely demonstrated. May a small but significant
adverse effect on cardiovascular risk in older age to obstruct the use
of calcium in preventing osteoporosis?
The process of vascular calcification is a complex: it is possible that
the increase in calcium supplements may influence vascular calcifi-
cation by altering mechanisms that regulate calcification.    atrix ve-
sicles are found in atherosclerotic calcification, along bone matrix pro-
teins, such as osteopontin, osteocalcin, matrix GLA protein, and sia-
loprotein. Calcified lesions contain also osteogenic regulatory factors,
such as RUNX2, Osterix and Wnts. Calcium is a key cofactor in blood
coagulation, and clot formation is a critical step in myocardial infarction,
so subtle changes in the coagulability of blood following calcium in-
gestion could be involved (14). The calcium sensing receptor is also
expressed in blood vessel walls, so changes in endothelial cells or
smooth muscle cells might be important. On the other hand the pro-
cess of arterial calcification is now recognised as being closely regulated
by a number of inhibitors including pyrophosphate and fetuin-A. The-
re is an urgent need for more research to gain insight into the me-
chanisms of the adverse vascular effect of calcium, since this might
lead to strategies for circumventing it. Moreover, more extensive data
about the incidence of cardiovascular adverse events coming from
randomized controlled intervention trials in osteoporosis, in which cal-
cium plus Vitamin D were utilized, might be achieved (15). 
We believe that the role of calcium supplements in osteoporosis ma-
nagement must be definitively ascertained. Encouragement of die-
tary calcium intake is reasonable, since the balance of current evi-
dence does not demonstrate a cardiovascular risk associated with
calcium from food, although there is little compelling evidence that
dietary calcium intake is associated with subsequent fracture risk.
It is possible that calcium that dietary advice may be the appropriate
way to attain an adequate calcium intake in most situations.
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